Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed) | RFA RM 22 024

Frequently Asked Questions (FAQs)

What is this NIH funding opportunity (RFA-RM-22-024) about?

This funding opportunity supports small, early-stage pilot studies that improve the functional understanding of a specific set of understudied but potentially druggable human proteins. The goal is to generate practical new data, validation results, and enabling tools that help the broader research community work on these targets and connect them to mechanisms relevant to human disease.

Which protein targets are in scope for this FOA?

The FOA is focused on non-olfactory G protein-coupled receptors (GPCRs), ion channels, and protein kinases that have been designated as eligible targets by the NIH Common Fund program Illuminating the Druggable Genome (IDG).

Does the FOA support research on olfactory GPCRs?

No. The opportunity is specifically limited to non-olfactory GPCRs (along with eligible ion channels and protein kinases designated by IDG).

What does "IDG-eligible targets" mean in this context?

It refers to human proteins in the specified target classes (non-olfactory GPCRs, ion channels, and protein kinases) that have been designated as eligible targets by the IDG program for this initiative.

What is the main purpose of these pilot projects?

The central purpose is to push functional understanding of these proteins beyond what the core IDG Centers can do on their own, while also field-testing and showcasing the usefulness of IDG-generated datasets, chemical and biological reagents, and experimental approaches when used by the wider research community.

What kind of project scope is expected?

The FOA emphasizes tightly focused projects, typically centered on one or a small number of IDG-eligible proteins. The intent is not to fund broad, multi-aim programs, but rather proof-of-concept efforts with clear, concrete deliverables.

What kinds of outputs or deliverables are expected?

Expected outputs include practical, incremental advances such as new functional data, validation experiments, or enabling tools. Examples mentioned include improved functional annotation, pathway placement, disease-relevant phenotyping, target engagement information, assay development, and other tools or datasets that make it easier for other scientists to study these targets.

Is the emphasis on basic discovery or on usable, shareable resources?

The emphasis is on generating usable outputs: evidence and resources that clarify what these proteins do and why they matter in disease biology, especially where existing knowledge is limited. A key theme is producing results and tools that are broadly informative beyond a single lab.

How does this FOA relate to the IDG program?

This FOA is designed to extend the characterization of IDG-eligible proteins and to validate and demonstrate the quality and utility of IDG resources (datasets, reagents, and approaches). It also aims to increase the visibility and adoption of those resources across the broader biomedical research community.

What does "demonstration" mean in the context of this opportunity?

It means the proposed work should help validate and showcase IDG-generated datasets and reagents in real-world use by researchers outside the core IDG Centers, illustrating their quality, utility, and applicability while extending what is known about eligible targets.

What grant mechanism is used for this opportunity?

This FOA uses the NIH R03 mechanism, which is designed for relatively small, early-stage, proof-of-concept style projects.

Is this intended for large, multi-year, multi-aim research programs?

No. The R03 mechanism and the stated purpose indicate the FOA is aimed at small pilot studies rather than large programs with extensive aims.

Are clinical trials allowed under this FOA?

No. The FOA is labeled "Clinical Trial Not Allowed," meaning the proposed research must remain non-clinical-trial research.

Who is the sponsoring NIH program area?

The opportunity falls under the NIH Common Fund and is associated with the Common Fund program Illuminating the Druggable Genome (IDG).

How is this opportunity categorized in federal assistance terms?

It is categorized as a discretionary grant in the health area and is associated with CFDA 93.310.

When was the funding opportunity created?

The opportunity was created on April 15, 2022.

What was the original application due date?

The original application due date was July 15, 2022.

Is this an always-open NIH mechanism?

No. The provided dates indicate it was a time-bounded call rather than an always-open mechanism.

What types of U.S. organizations are eligible to apply?

Eligibility is broad and includes public and private institutions of higher education; nonprofits (with or without 501(c)(3) status); for-profit organizations (including small businesses and for-profits other than small businesses); and many government entities (state, county, city/township, special districts), as well as independent school districts and public housing authorities/Indian housing authorities.

Are minority-serving institutions and certain special categories of organizations explicitly included?

Yes. The FOA explicitly welcomes applicants such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISI). It also includes faith-based or community-based organizations, regional organizations, U.S. territories or possessions, eligible federal agencies, and other standard federal applicant categories listed in the opportunity.

Can foreign organizations or foreign institutions apply directly?

No. Foreign organizations and foreign institutions are not eligible to apply directly under this opportunity.

Can a U.S. organization include a non-U.S. component as the applicant?

No. Non-U.S. components of U.S. organizations are not eligible as applicant components.

Are any foreign activities allowed at all?

Possibly. The FOA notes that "foreign components" (as NIH defines them) may be allowed, meaning certain parts of the work could potentially be conducted outside the U.S. under NIH policy when appropriately justified and approved.

What research areas does the FOA prioritize within the target families?

The FOA prioritizes work that produces additional evidence and resources clarifying protein function and relevance to disease biology, particularly where current knowledge is thin. The emphasis is on strengthening functional understanding and tractability for therapeutic exploration.

What is the bigger goal of this funding opportunity in plain terms?

It is a targeted push to accelerate discovery around overlooked members of major drug-target families by funding focused pilots that deliver usable data and tools and that reinforce and extend the value of the IDG program for the wider scientific community.